Navigation Links
YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Date:3/15/2010

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company. The Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a highly selective JAK 1/2 small molecule inhibitor, CYT997, an orally bioavailable, potent, vascular disrupting agent (VDA) and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The clinical stage products discovered by Cytopia Ltd (YM Australia since January 2010'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen Microsoft ... help it move to Office 365.      ... provides small to medium-sized companies in the bio-tech sector ... aspects of the purchasing cycle to help them obtain ...
(Date:7/1/2015)... RESEARCH TRIANGLE PARK, N.C. and ... -- Leading agricultural research firm AgBiome, and Genective, key ... partnership to accelerate the discovery of new generations ... new traits for insect control to counter the ... to partner with Genective, aligning AgBiome,s unique insect ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... 1, 2015 InferMed , ... will ... evidence-based clinical s olutions suite   ... information products and services, announced today the acquisition of  InferMed ... (CDS) technology company. InferMed,s Arezzo technology supports clinicians ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... Mich., Dec. 18 Neogen Corporation (Nasdaq: NEOG ) ... of FY 2010, which ended Nov. 30, increased 18% from ... split effective Dec. 15, net income in the quarter rose ... Neogen,s second quarter net income of $4,610,000 set another quarterly ...
... , , , NEW HAVEN, ... of web-enabled database software for biomedical researchers, has been ... a working, web-enabled database software prototype that can be ... and is easy to use. , The National Science ...
... , - Therapure Biopharma to perform fill/finish of nimotuzumab ... Allan, Chairman and CEO of YM BioSciences Inc. and ... today announced the signing of an agreement under which ... nimotuzumab, the humanized monoclonal antibody licensed to YM,s majority-owned ...
Cached Biology Technology:Neogen Reports 18% Increase in Net Income 2Neogen Reports 18% Increase in Net Income 3Neogen Reports 18% Increase in Net Income 4Neogen Reports 18% Increase in Net Income 5Neogen Reports 18% Increase in Net Income 6Neogen Reports 18% Increase in Net Income 7Prometheus Research Awarded National Science Foundation Grant for Easy to Use, Web-Enabled Database Software 2Prometheus Research Awarded National Science Foundation Grant for Easy to Use, Web-Enabled Database Software 3YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 2YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 3YM BioSciences Inc. and Therapure Biopharma Inc. Announce Contract 4
(Date:6/17/2015)... June 17, 2015  Crossmatch™, a leading provider ... its U.are.U ® 4500 fingerprint readers have ... Eateries, Inc., a San Jose, CA ... increase security, improve accountability and reduce fraud at ... non-repudiable identity confirmation for employee sign in and ...
(Date:6/16/2015)... -- With the increasing number and severity of data breaches ... recent compromise of Federal employee data from OPM,s ... government agencies. HYPR Corp. announced today that ... has been submitted for testing and approval of Federal ... tamper proofing. The proliferation of security ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... communicated that it will amount to at least 340 MSEK ... to the rapid increase in market growth and orders received ... communicated guidance that revenue for 2015 will exceed 1,500 MSEK ... to approximately 2,200 MSEK. Due to receipt of ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... collaboration with the Technical University of Braunschweig (TUBS), Germany ... autonomous unmanned aerial vehicles (UAVs) in Antarctica. This is ... in the Antarctic and the successful flights open up ... the harshest and remotest environment on Earth. Dr ...
... study, researchers taking advantage of improvements in satellite sensor ... of pollution from East Asian forest fires, urban exhaust, ... North America. China, the worlds most populated country, ... urban areas, and considerable expansion in automobile use over ...
... Human diseases and social networks would seem to ... of these two lies a network,communities within the ... In a recent paper in Physical Review E ... computer science and engineering and of genetics, and ...
Cached Biology News:Unmanned aerial vehicles mark robotic first for British Antarctic Survey 2NASA satellite measures pollution from east Asia to North America 2NASA satellite measures pollution from east Asia to North America 3Algorithm finds the network -- for genes or the Internet 2Algorithm finds the network -- for genes or the Internet 3
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Analysis Note: Protein determined by ... 3.2 M (NH 4 ) ... 7.0 Preparation Note: Affinity purified ... suspension • Additives: MgCl 2 ...
... miRNA Bioarray Essentials Kit provides all the necessary ... of the mir Vana miRNA Bioarrays when ... using Ambions mir Vana miRNA Labeling Kit. ... (Bioarray ID BA10001) that should be spiked into ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
Biology Products: